| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$145.2M | ROE | −58.88% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company identifying, developing, and commercializing medicines for cancers with unmet medical needs. Its lead candidate, firmonertinib, is a tyrosine kinase inhibitor being evaluated across a range of EGFR mutations in non-small cell lung cancer, including a Phase 3 trial for advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations. It is also developing ARR-217, an antibody drug conjugate for gastrointestinal cancers, and additional candidates.
| Market Cap | $1.40B | Trading Days | 621 |
| 52W High | 35.83 |
| 52W Low | 16.10 |
| % Off High | −16.33% |
| YTD | 49.01% | 1Y | 43.24% |
| Since incept. (ann.) | 17.56% |
| Ann. Volatility (1Y) | 57.40% | Ann. Volatility (3Y) | 54.64% |
| Sharpe (1Y) | 0.93 | Sharpe (3Y) | 0.57 |
| Max Drawdown (1Y) | −24.22% | Max Drawdown (3Y) | −54.25% |
| Beta (3Y, vs SPY) | 1.36 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | $1.38B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.42B | — |
| PRGO | PERRIGO Co plc | $1.43B | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.46B | — |
| CMPS | COMPASS Pathways plc | $1.46B | — |
| HROW | HARROW, INC. | $1.47B | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.48B | 30.6 |
| XNCR | Xencor Inc | $1.48B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.28B | — |
| SEPN | Septerna, Inc. | $1.53B | — |
| ARDX | ARDELYX, INC. | $1.26B | — |